Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

By Mahadevan Daruka   Sutton Gregory   Arteta-Bulos Rafael   Bowden Chris   Miller Paul   Swart Rachel   Walker Mark   Haluska Paul   Munster Pamela   Marshall John   Hamid Omid   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 467-473

Springer Publishing Company

Access to resources Recommend Favorite

Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

By Xin Ying   Shen Xiang-di   Cheng Long   Hong De-fei   Chen Bin  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 711-719

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

By Macaulay V. M.   Middleton M. R.   Protheroe A. S.   Tolcher A.   Dieras V.   Sessa C.   Bahleda R.   Blay J.-Y.   LoRusso P.   Mery-Mignard D.   Soria J.-C.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 784-791

Oxford University Press

Access to resources Recommend Favorite

Inhibiting the Interaction of cMET and IGF-1R with FAK Effectively Reduces Growth of Pancreatic Cancer Cells in vitro and in vivo

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 4, 2013-01 ,pp. : 595-602

Bentham Science Publishers

Access to resources Recommend Favorite

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

By                    

Experimental and Therapeutic Medicine, Vol. 3, Iss. 4, 2012-01 ,pp. : 599-602

Spandidos Publications

Access to resources Recommend Favorite